newsfilter
← Latest News
Earnings Call Transcripts·

Jefferies Global Healthcare Conference in London - ALX ONCOLOGY HOLDINGS INC

  • Financial Performance:

    • Secured $150 million in equity financing in January through investors including RA Blackstone and Orbimed, ensuring sufficient capital to execute development milestones.
    • Currently in pre-revenue stage; no specific revenue, earnings, or profit margin figures reported as the company focuses on clinical development.
    • Cash position described by management as "well-funded" to support operations through the end of next year.
  • Guidance and Future Outlook:

    • ALX2004 (EGFR ADC): Updated guidance to report data on 35–40 patients in the upcoming KOL event in December, with 15+ patients at efficacious doses.
    • ALX-Evo (HER2 ADC): Updated guidance to reach 120 patients in the ongoing Phase 2 study by the end of the current year.
    • Strategic Goal: Aim to be "pivotal trial ready" by the end of 2026 to enable registration studies (Phase 3) starting in 2027.
    • Long-term Path: Strategy targets moving from late-line (4th line) to earlier lines of therapy (2nd line monotherapy, potentially front-line combinations) pending data success.
  • Business Segments and Product Lines:

    • ALX2004 (EGFR-targeted ADC):
      • Utilizes a novel epitope binding (metuzumab) rather than the industry-standard cetuximab to reduce toxicity and allow combination with existing therapies.
      • Payload is a Topoisomerase I inhibitor (Topo-1) with a Drug-Antibody Ratio (DAR) of 8, designed for high potency.
      • Primary indications: Head and neck, lung, and esophageal cancers; enrollment focused on head and neck and lung due to higher EGFR expression and commercial potential.
    • ALX-Evo:
      • HER2-targeted therapy currently in a non-registrational Phase 2 study for patients who have progressed on HER2+ therapy.
      • Enrollment is tracking faster than expected with high investigator enthusiasm.
    • ALX-001 (CD47/Bispecific):
      • Program has treated over 800 patients; characterized as a targeted immunotherapy (IO) play with a bifurcated mechanism to separate "eat me" and "don't eat me" signals.
      • Focus shifted to identifying specific biomarkers and optimal patient populations based on prior dosing experience.
  • Market and Competitive Landscape:

    • EGFR Space: Competitive landscape includes bispecifics (e.g., PCDO, AMI) and ADCs; ALX differentiates via unique metuzumab epitope binding.
    • Differentiation: The metuzumab binding site is distinct from cetuximab, potentially allowing use after resistance to cetuximab-based therapies and enabling unique combinations (e.g., with PETO or AMI) similar to the dual HER2 strategy in breast cancer.
    • Head and Neck: ALX2004 aims to be the first Topoisomerase ADC in this class; potential to compete with next-gen bispecifics in the 2nd-line setting.
    • Lung Cancer: Focus on "wild-type" squamous cell carcinoma where EGFR is highly expressed, an area where competitors like Datu and others face limited opportunity.
  • Risks and Challenges:

    • Toxicity: Primary risk is EGFR-related toxicity (rash), historically 70–90% with cetuximab; ALX targets reducing this to ≤30% (Grade 1/2 only).
    • Chemotherapy Toxicities: Potential for myelosuppression, nausea, vomiting, and mucositis due to the Topo-1 payload, though management views these as manageable with supportive care.
    • Clinical Benchmarks: High unmet need but difficult to demonstrate efficacy in 4th-line populations where standard care ORR is 5–10%; company targets >20% (outstanding) or >30% (transformational) ORR.
    • Regulatory Path: Final trial design and approval path (single-arm vs. randomized) remain data-dependent.
  • Management Commentary and Tone:

    • Tone: Highly confident and optimistic, particularly regarding the ALX2004 data update and the strategic advantage of the unique epitope.
    • Confidence: Management expressed strong belief that their molecule offers a "wide therapeutic window" and can compete with standard-of-care bispecifics.
    • Transparency: Committed to transparent data sharing, including swimmer plots and waterfall plots for all 15+ efficacy patients.
  • Analyst Questions and Answers:

    • Q: Safety Profile: Management confirmed the primary safety focus is minimizing rash rates to ≤30% (ideally Grade 1/2) compared to historical 70–90% rates for cetuximab.
    • Q: Efficacy Expectations: Targeting >20% ORR in a 4th-line population is considered "outstanding," with >30% viewed as "transformational."
    • Q: Dosing Strategy: Dose escalation moved rapidly; the goal is to identify the therapeutic window and backfill patients within that range for the data readout.
    • Q: Tumor Selection: Enrollment is not balanced across all basket types; focus is heavily on head and neck and lung, with minimal esophageal and CRC patients.
    • Q: Combination Potential: Unique ability to combine ALX2004 with other EGFR therapies (like PETO or AMI) due to different binding pockets, unlike current ADCs/bispecifics which share epitopes.
    • Q: Regulatory Strategy: Single-arm accelerated approval is possible for 2nd-line head and neck (citing AMI precedent); front-line and lung indications may require randomized trials depending on data.
  • Other Key Points:

    • Biomarker Strategy: The CD47 program is now viewed strictly as a targeted IO play, with drug selection driven by specific biomarker identification from the 800+ patient dataset.
    • Market Opportunity: The team views the EGFR ADC space as having a "screaming unmet need," particularly in the post-HER2 and HER2+ late-line settings.
    • Capital Allocation: Recent financing provides runway to execute the "next 12 months" of milestones without immediate dilution concerns.
Company
ALX ONCOLOGY HOLDINGS INC
Keywords
ALX ONCOLOGY HOLDINGS INC